MOMakoto Oketani

Makoto Oketani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Makoto Oketani has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C

    by Kumiko Mera, Hirofumi Uto, Seiichi Mawatari, Akio Ido, Yozo Yoshimine, Tsuyoshi Nosaki, Kohei Oda, Kazuaki Tabu, Kotaro Kumagai, Tsutomu Tamai, et al.

    Apoptosis inhibitor of macrophage (AIM) and adipocytokines are involved in the metabolic syndrome, which has been putatively associated with the progression of chronic hepatitis C (CHC). However, the association between these cytokines and CHC is not fully elucidated. The aim of this study is to test whether serum levels of AIM and adipocytokines are associated with histological features, homeostasis model assessment-insulin resistance index (HOMA-IR), or whole body insulin sensitivity index (WBISI) in CHC patients.


  • Management of hepatitis B virus-related acute liver failure

    by Makoto Oketani, Hirofumi Uto, Akio Ido, Hirohito Tsubouchi

    Hepatitis B virus (HBV) is the most important cause of acute liver failure (ALF) in Eastern countries. HBV-related ALF may occur after acute HBV infection (A-ALF) or during acute exacerbation (flare) of chronic HBV infection (C-ALF). C-ALF may occur spontaneously or as a result of the effect of immunosuppression due to chemotherapeutic or immunosuppressive agents. The definition of HBV-related ALF is uncertain, because different diagnostic criteria are used in C-ALF, which may present as acute-on-chronic liver failure. Although the pathogenesis differs in the two subgroups of ALF, the symptoms and biochemical parameters can be similar. High titers of immunoglobulin M hepatitis B core antibody and lower viral loads are frequent in A-ALF as compared with C-ALF. The prognosis of C-ALF is significantly poor as compared with that of A-ALF. In C-ALF, most immunosuppression-mediated reactivation of hepatitis B results in fatality. Many case series or case-control studies have not demonstrated the survival benefit of nucleos(t)ide treatment. This treatment failure is probably related to delayed initiation of nucleos(t)ide treatment and viral suppression. Treatment with nucleos(t)ide analogs should be started immediately and should be continued regardless of subgroups of HBV-related ALF. Liver transplantation is the only treatment option that improves the prognosis of HBV-related ALF. Patients under consideration for transplantation should be given nucleos(t)ide analogs as prophylaxis to reduce the likelihood of post-transplant HBV recurrence.


  • Classification of the etiologies of acute liver failure in Japan -A Report by the Intractable Hepato-Biliary Diseases Study Group of Japan-

    by Satoshi Mochida, Yasuhiro Takikawa, Nobuyuki Nakayama, Makoto Oketani, Takafumi Naiki, Yoshiyuki Yamagishi, Keiichi Fujiwara, Takafumi Ichida, Hirohito Tsubouchi


  • Open Access

    Dietary fructose enhances the incidence of precancerous hepatocytes induced by administration of diethylnitrosamine in rat

    by Ryo Kumamoto, Hirofumi Uto, Kohei Oda, Rie Ibusuki, Shirou Tanoue, Shiho Arima, Seiichi Mawatari, Kotaro Kumagai, Masatsugu Numata, Tsutomu Tamai, et al.

    Background: Nonalcoholic fatty liver disease (NAFLD) is a risk for hepatocellular carcinoma (HCC), but the association between a high-fructose diet and HCC is not fully understood. In this study, we investigated whether a high-fructose diet affects hepatocarcinogenesis induced by administration of diethylnitrosamine (DEN). Methods: Seven-week-old male Sprague–Dawley rats were fed standard chow (controls), a high-fat diet (54% fat), or a high-fructose diet (66% fructose) for 8 weeks. All rats were given DEN at 50 μg/L in drinking water during the same period. Precancerous hepatocytes were detected by immunostaining of the placental form of glutathione-S-transferase (GST-P). The number of GST-P-positive hepatocytes was assessed in liver specimens. Results: Serum levels of total cholesterol were similar among the three groups, but serum triglyceride, fasting blood glucose, and insulin levels were higher in the high-fructose group compared to the high-fat group. In contrast, hepatic steatosis was more severe in the high-fat group compared with the high-fructose and control groups, but the incidence of GST-P-positive specimens was significantly higher in the high-fructose group compared to the other two groups. The average number of GST-P-positive hepatocytes in GST-P positive specimens in the high-fructose group was also higher than those in the other two groups. This high prevalence of GST-P-positive hepatocytes was accompanied by higher levels of 8-hydroxydeoxyguanosine in serum and liver tissue. Conclusions: These results indicate that dietary fructose, rather than dietary fat, increases the incidence of precancerous hepatocytes induced by administration of DEN via insulin resistance and oxidative stress in rat. Thus, excessive fructose intake may be a potential risk factor for hepatocarcinogenesis.


  • Open Access

    Etiology and prognosis of fulminant hepatitis and late‐onset hepatic failure in Japan: Summary of the annual nationwide survey between 2004 and 2009

    by Makoto Oketani, Akio Ido, Nobuaki Nakayama, Yasuhiro Takikawa, Takafumi Naiki, Yoshiyuki Yamagishi, Takafumi Ichida, Satoshi Mochida, Saburo Onishi, Hirohito Tsubouchi, et al.

    Aim: To summarize the annual nationwide survey on fulminant hepatitis (FH) and late‐onset hepatic failure (LOHF) between 2004 and 2009 in Japan.Methods: The annual survey was performed in a two‐step questionnaire process to detail the clinical profile and prognosis of patients in special hospitals.Results: Four hundred and sixty (n = 227 acute type; n = 233 subacute type) patients had FH and 28 patients had LOHF. The mean age of patients with FH and LOHF were 51.1 ± 17.0 and 58.0 ± 14.4 years, respectively. The causes of FH were hepatitis A virus in 3.0%, hepatitis B virus (HBV) in 40.2%, other viruses in 2.0%, autoimmune hepatitis in 8.3%, drug allergy‐induced in 14.6% and indeterminate etiology in 29.6% of patients. HBV reactivation due to immunosuppressive therapy was observed in 6.8% of FH patients. The short‐term survival rates of patients without liver transplantation (LT) were 48.7% and 24.2% for the acute and subacute type, respectively, and 13.0% for LOHF. The prognosis was poor in patients with HBV reactivation. The implementation rate for LT in FH patients was equivalent to that in the previous survey. The short‐term survival rates of total patients, including LT patients, were 54.2% and 40.8% for the acute and subacute type, respectively, and 28.6% for LOHF.Conclusion: The demographic features and etiology of FH patients has gradually changed. HBV reactivation due to immunosuppressive therapy is problematic. Despite advances in therapeutic approaches, the prognosis of patients without LT has not improved.


  • Open Access

    Fatty liver in men is associated with high serum levels of small, dense low-density lipoprotein cholesterol

    by Kaori Hosoyamada, Hirofumi Uto, Yasushi Imamura, Yasunari Hiramine, Eriko Toyokura, Yoshihiro Hidaka, Tomomi Kuwahara, Ken Kusano, Kazuto Saito, Makoto Oketani, et al.

    Our study addressed potential associations between fatty liver and small, dense low-density lipoprotein cholesterol (sd-LDL-C) levels using a cross-sectional analysis. We enrolled 476 male subjects. Serum sd-LDL-C concentrations were determined using precipitation assays. Subjects were divided into four groups based on triglyceride (TG) and LDL-C levels: A, TG < 150 mg/dl and LDL-C < 140 mg/dl; B, TG < 150 mg/dl and LDL-C ≥ 140 mg/dl; C, TG ≥ 150 mg/dl and LDL-C < 140 mg/dl; and D, TG ≥ 150 mg/dl and LDL-C ≥ 140 mg/dl. sd-LDL-C levels and the prevalence of fatty liver were significantly higher in groups B, C, and D than in group A. Subjects were also categorized into four groups based on serum sd-LDL-C levels; the prevalence of fatty liver significantly increased with increasing sd-LDL-C levels. Additionally, logistic regression analysis revealed an independent association between sd-LDL-C concentrations and fatty liver using such potential confounders as obesity and hyperglycemia as variables independent of elevated TG or LDL-C levels. Fatty liver is a significant determinant of serum sd-LDL-C levels independent of the presence of obesity or hyperglycemia. Fatty liver may alter hepatic metabolism of TG and LDL-C, resulting in increased sd-LDL-C levels.


  • Mo1840 Serum Levels of Apoptosis Inhibitor of Macrophage (AIM) are Associated With Hepatic Fibrosis and Insulin Resistance in Patients With Hepatitis C Virus-Associated Liver Disease

    by Kumiko Mera, Hirofumi Uto, Yuko Sato, Yozo Yoshimine, Kohei Oda, Dai Imanaka, Akiko Saishoji, Tsutomu Tamai, Tsuyoshi Nosaki, Akihiro Moriuchi, et al.

  • Su1950 Hypertension Exacerbates Hepatic Fibrosis Induced by a Choline-Deficient L-Amino Acid-Defined Diet in Rats

    by Shiho Arima, Hirofumi Uto, Rie Ibusuki, Ryo Kumamoto, Shirou Tanoue, Seiichi Mawatari, Takeshi Kure, Masatsugu Numata, Hitoshi Setoyama, Hiroshi Fujita, et al.

  • Open Access

    Hepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice

    by Akio Ido, Naohisa Yamaji, Akihiro Moriuchi, Masatsugu Numata, Hitoshi Setoyama, Tsutomu Tamai, Keita Funakawa, Hiroshi Fujita, Toshio Sakiyama, Hirofumi Uto, et al.

    Hepatocyte growth factor (HGF), which facilitates the repair of injured mucosa, has the potential to be a new therapeutic agent for inflammatory bowel disease (IBD). However, given that the incidence of colorectal cancer increases continuously with disease duration in patients with IBD, the fact that HGF is a potent mitogen for intestinal epithelial cells may further heighten the risk of bowel cancer in this patient population. In this study, we examined the effects of recombinant HGF on colorectal cancer development in mice with or without experimentally induced colitis. Although HGF stimulated proliferation of colonic epithelial cells in normal mucosa, the development of colorectal cancer induced by repeated injection of azoxymethane (AOM) was significantly inhibited by HGF treatment. In a mouse model of colitis-associated cancer, colorectal cancer frequently developed despite only a single injection of AOM prior to three cycles of dextran sulfate sodium administration. However, HGF treatment significantly facilitated the repair of injured mucosa, leading to inhibition of colorectal cancer development in a dose-dependent manner. Thus, HGF-induced repair of injured mucosa inhibits rather than accelerates the development of colorectal cancer, and these results also suggest the importance of blocking the cycles of mucosal injury and repair to prevent colitis-associated colorectal cancer.